Myovant hormonal drug Myfembree has won FDA approval as a treatment for uterine fibroid bleeding. The regulatory decision clears the way for the pill to compete against a similar AbbVie drug, but with a dosing advantage.
The Sumitomo Dainippon-Roivant Alliance will be wholly owned by Sumitomo, which is also taking control of five companies - and potentially six more - from Ramaswamy's Vant family of firms.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Alyvant will be focused on connecting de-identified patient data with physician data to connect patient populations with suitable medications.
Myovant is making the most of its $218M IPO. The women's health company has launched two international Phase 3 trials for its lead compound, relugolix, with another three planned for the first half of 2017 — just in time for its one-year anniversary.
Myovant Sciences has orchestrated the largest biotech IPO of the year thus far, five months after their launch and with just nine employees on payroll.